Value of EUS-guided parenchymal liver biopsy. A randomized controlled trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00028038

Enrollment

Registered

2022-02-04

Start date

2022-02-13

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K74 K71

Interventions

Group 1: EUS-guided liver biopsy Group 2: percutaneous Ultrasound-guided liver biopsy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Written consent, elevated liver enzymes, need for staging of viral, autoimmune or metallic liver disease.

Exclusion criteria

Exclusion criteria: Age1.5, Limited capacity for consent.

Design outcomes

Primary

Measure	Time frame
Periinterventional pain measured with the numeric pain score.	—

Secondary

Measure	Time frame
Complication rate, length of biopsy core, Count of Portal Fields, Count of biopsy cores, allover length of all biopsy cores, technical success.	—

Countries

Germany

Contacts

Public ContactDavid Albers

Elisabeth-Krankenhaus Essen, Abteilung für Gastroenterologie

d.albers@contilia.de0201-897-3101

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026